September 10, 2007 - Philips is showcasing its complete preclinical product portfolio, including a new Preclinical Workspace, the MOSAIC HP preclinical PET system with new software version and the NanoSPECT/CT, at the Joint AMI/SMI Molecular Imaging Conference, Sept. 7 to Sept. 11, in Providence, RI.
Philips’ new Preclincial Workspace offers a comprehensive solution for imaging analylitics, which includes complete image processing, quantification, and visualization tools dedicated to preclinical imaging. The new Preclinical Workspace also features project-centric and hypothesis-driven workflow that supports four modalities: PET, CT, SPECT and MRI, and is based on an expandable platform to accommodate current and future preclinical imaging needs. The Workspace can be used in conjunction with Philips’ MOSAIC HP and NanoSPECT/CT products for centralized preclinical processing.
Also on display is the Philips MOSAIC HP, equipped with high performance LYSO detector technology. The dedicated preclinical PET system delivers flexibility and efficiency for a wide range of preclinical research applications in oncology, cardiology and neurology. MOSAIC HP’s extra-long imaging bore and long axial field of view allows imaging of a variety of research subjects and bio-distribution studies on a whole subject in a single scan. At AMI/SMI Philips is launching a new software release for the MOSAIC HP that will add several new functionalities and enhancements, such as cardiac gating application in list mode, CT attenuation correction and connectivity to the new Preclinical Workspace.
Rounding out Philips’ tri-modality preclinical product offering is the NanoSPECT/CT. NanoSPECT/CT reportedly helps accelerate preclinical research, the discovery of new targeted biomarkers and the development and validation of new molecular diagnostic and therapeutic applications. The system enables fast, dynamic SPECT and dual isotope imaging with ultra-high sensitivity and sub-millimeter resolution.
For more information: www.medical.philips.com
May 14, 2024 
